Senescent Cell Purification and Removal via G2-p53-PLK1 Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current techniques lack a stable method for purifying senescent cells and effectively removing them to address age-related diseases and extend healthy life expectancy.
Innovation Solution
A method involving synchronization of cells in the G2 phase, activation of p53 protein, and inhibition of polo-like kinase 1 (PLK1) activity, followed by inhibiting glutaminolysis using a glutaminase inhibitor to induce selective cell death in senescent cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional methods are used to prepare senescent cells, then cell population can be obtained, but the cells cannot be sufficiently purified and stably prepared
Solution Approach 1:
The invention segments the senescent cell preparation process into distinct phases: G2 phase synchronization, p53 activation, and PLK1 inhibition. This segmentation allows each step to be optimized and controlled independently, achieving both high purification and stable preparation of senescent cells
Solution Approach 2:
The invention performs preliminary synchronization of cells to the G2 phase before inducing senescence. This preliminary action ensures that all cells are in the same cell cycle stage, which is critical for achieving uniform and stable senescent cell preparation with high purification
2Object-affected harmful factors
If senescent cells are removed to extend healthy life expectancy, then age-related diseases can be prevented, but no effective method exists to selectively remove senescent cells in vivo
Solution Approach 1:
The invention uses PLK1 inhibition as an intermediary mechanism to achieve selective senescent cell removal. By targeting PLK1, which is essential for senescent cell survival, the invention provides a feasible method to remove senescent cells in vivo, thereby preventing age-related diseases
Solution Approach 2:
The invention changes the biochemical parameters of senescent cells by inhibiting PLK1 activity, which alters their survival characteristics. This parameter change enables selective removal of senescent cells while sparing healthy cells, providing an effective therapeutic approach
Data Source
AI summary
Solutions to the problem of the invention are a method for selectively killing or removing a senescent cell, substance identification, and a method for purifying a senescent cell. Specifically, the invention includes an agent for removing a senescent cell, which is a drug for removing an in vivo senescent cell, the agent containing an inhibitor for glutaminase as an active ingredient, and a pharmaceutical composition containing the agent. The invention further includes a method for preparing a senescent cell, including the following steps (a) to (c): (a) synchronizing a cell with the G2 phase; (b) activating an intracellular p53 protein in the cell synchronized with the G2 phase; and (c) inhibiting polo-like kinase 1 (PLK1) activity in the cell treated in the step (b).